Y.ZhaoM.ZhaoK
Clinical trials and meta-analyses consistently show that DPP-4 inhibitors produce a modest but clinically meaningful reduction in HbA1c , typically in the range of: 0.5% to 1.0% (approximately 5.5 to 11 mmol/mol) when used as monotherapy or add-on therapy Reductions at the higher end of this range are more likely when baseline HbA1c is significantly elevated For example, sitagliptin has demonstrated reductions of around 0.60.8% in randomised controlled trials, while vildagliptin and saxagliptin show broadly comparable efficacy
Fourth, due to limited data, crucial parameters linked to obesity or EDs, including laboratory biomarkers, could not be analyzed
-DIURETIC: Stimulates diuresis, helping remove retained fluids and detoxifying the organism
Loss of control eating a hallmark of binge episodes was also significantly reduced
In this article, we will delve into the hot topics that ignited conversations, sparked debates, and paved the way for a future of enhanced understanding and treatment of this complex disease